CLOs on the Move

Cordant Health Solutions

www.cordanths.com

 
Based in Denver, Cordant Health Solutions™ provides innovative tools for monitoring and managing behavioral health, chronic pain and criminal justice cases. Our unique programs include pharmacy, clinical laboratory and analytic tools that provide actionable information to protect prescribers, improve outcomes and contain costs. As a leader in rigorous quality and compliance standards, Cordant is committed to developing groundbreaking solutions for payers, clinicians and organizations involved in the substance use disorder, criminal justice and pain management markets. Cordant offers unique risk assessment, monitoring and management tools through its integrated network of laboratories and high-touch pharmacies specializing in the management and dispensing ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.cordanths.com
  • 12015 East 46th Avenue Suite 220
    Denver, CO USA 80239
  • Phone: 844.848.5955

Executives

Name Title Contact Details
Regina Morano
Chief Regulatory and Compliance Officer Profile

Similar Companies

Roche Insulin Delivery Systems

Roche Insulin Delivery Systems is a Fishers, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hello Phoenix

Hello Phoenix is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

College of Registered Nurses of British Columbia

College of Registered Nurses of British Columbia is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

medSage Technologies LLC

medSage Technologies LLC is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Pittsburgh, PA. To find more information about medSage Technologies LLC, please visit www.medsagetechnologies.com

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic